• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Star Equity Holdings, Inc. Appoints Rick Coleman as CEO

    4/1/22 8:00:00 AM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $STRR alert in real time by email

    OLD GREENWICH, Conn., April 01, 2022 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP))) ("Star Equity" or the "Company"), a diversified holding company, announced today the appointment of Richard ("Rick") K. Coleman, Jr. as Chief Executive Officer, effective April 1, 2022. In addition, Mr. Coleman will be nominated to serve as a director at the Company's upcoming annual meeting of shareholders.

    Mr. Coleman is a seasoned executive who brings to Star Equity extensive CEO leadership and board-level experience with numerous public and private companies. He was appointed as Star Equity's Chief Operating Officer in January 2022 and has provided valuable insights and direction to our leadership and operating teams since that time. As CEO, Mr. Coleman will lead Star Equity's business growth and oversee its overall operations.

    "Rick brings extensive experience and leadership in the public company executive suite," said Jeff Eberwein, Star Equity's Executive Chairman. "Over the course of his career, he has provided executive leadership and driven operational excellence at various companies, particularly those experiencing rapid or fundamental strategic change. Given his strong background in various businesses, we look forward to leveraging his expertise to aggressively grow the Company."

    "Since joining Star Equity, I've been impressed both by the strength of our team and the magnitude of our opportunities for the future. The entire Star Equity team is not only incredibly talented, but also laser focused on generating shareholder value. I look forward to working alongside Jeff, the management team, and the board as we work together to execute our strategic business plan," said Mr. Coleman.

    Mr. Coleman brings more than 30 years of executive leadership experience with extensive expertise in business development, operational excellence, and acquisitions. He has served in a variety of senior executive roles, including President, CEO, and director of Command Center Inc., a provider of flexible on-demand employment solutions; President, CEO, and director of Crossroads Systems, Inc., a global provider of data archive solutions; CEO of Vroom Technologies Inc.; Chief Operating Officer of MetroNet Communications; and President of US West Long Distance. He also has held significant officer-level positions with Frontier Communications, Centex Telemanagement, and Sprint Communications.

    He began his career as an Air Force Telecommunications Officer managing Department of Defense R&D projects. He has also served as an adjunct professor for Regis University's graduate management program and is a guest lecturer for Denver University's Pioneer Leadership Program, focusing on leadership and ethics. Mr. Coleman holds a master's degree in Business Administration from Golden Gate University and is a graduate of the United States Air Force Communications System Officer School. He holds a Bachelor of Science Degree from the United States Air Force Academy and also has completed leadership, technology, and marketing programs at Kansas University, UCLA, and Harvard Business School.

    About Star Equity Holdings, Inc.

    Star Equity Holdings, Inc. is a diversified holding company with three divisions: Healthcare, Construction, and Investments.

    Healthcare

    Our Healthcare division designs, manufactures, and distributes diagnostic medical imaging products and provides mobile imaging services. Our Healthcare division operates in two businesses: (i) diagnostic services and (ii) diagnostic imaging. The diagnostic services business offers imaging services to healthcare providers as an outsourced alternative to purchasing and operating their own equipment. The diagnostic imaging business develops, sells, and maintains solid-state gamma cameras.

    Construction

    Our Construction division manufactures modular housing units for commercial and residential real estate projects and operates in two businesses: (i) modular building manufacturing and (ii) structural wall panel and wood foundation manufacturing, including building supply distribution operations for professional builders.

    Investments

    Our Investments division manages and finances the Company's real estate assets and investments.

    Forward-Looking Statements

    "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this release that are not statements of historical fact are hereby identified as "forward-looking statements" for the purpose of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking Statements include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to acquisitions and related integration, development of commercially viable products, novel technologies, and modern applicable services, (ii) projections of income (including income/loss), EBITDA, earnings (including earnings/loss) per share, free cash flow (FCF), capital expenditures, cost reductions, capital structure or other financial items, (iii) the future financial performance of the Company or acquisition targets and (iv) the assumptions underlying or relating to any statement described above. Moreover, forward-looking statements necessarily involve assumptions on the Company's part. These forward-looking statements generally are identified by the words "believe", "expect", "anticipate", "estimate", "project", "intend", "plan", "should", "may", "will", "would", "will be", "will continue" or similar expressions. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events, or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described above as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the substantial amount of debt of the Company and the Company's ability to repay or refinance it or incur additional debt in the future; the Company's need for a significant amount of cash to service and repay the debt and to pay dividends on the Company's preferred stock; the restrictions contained in the debt agreements that limit the discretion of management in operating the business; legal, regulatory, political and economic risks in markets and public health crises that reduce economic activity and cause restrictions on operations (including the recent coronavirus COVID-19 outbreak); the length of time associated with servicing customers; losses of significant contracts or failure to get potential contracts being discussed; disruptions in the relationship with third party vendors; accounts receivable turnover; insufficient cash flows and resulting lack of liquidity; the Company's inability to expand the Company's business; unfavorable changes in the extensive governmental legislation and regulations governing healthcare providers and the provision of healthcare services and the competitive impact of such changes (including unfavorable changes to reimbursement policies); high costs of regulatory compliance; the liability and compliance costs regarding environmental regulations; the underlying condition of the technology support industry; the lack of product diversification; development and introduction of new technologies and intense competition in the healthcare industry; existing or increased competition; risks to the price and volatility of the Company's common stock and preferred stock; stock volatility and in liquidity; risks to preferred stockholders of not receiving dividends and risks to the Company's ability to pursue growth opportunities if the Company continues to pay dividends according to the terms of the Company's preferred stock; the Company's ability to execute on its business strategy (including any cost reduction plans); the Company's failure to realize expected benefits of restructuring and cost-cutting actions; the Company's ability to preserve and monetize its net operating losses; risks associated with the Company's possible pursuit of acquisitions; the Company's ability to consummate successful acquisitions and execute related integration, as well as factors related to the Company's business including economic and financial market conditions generally and economic conditions in the Company's markets; failure to keep pace with evolving technologies and difficulties integrating technologies; system failures; losses of key management personnel and the inability to attract and retain highly qualified management and personnel in the future; and the continued demand for and market acceptance of the Company's services. For a detailed discussion of cautionary statements and risks that may affect the Company's future results of operations and financial results, please refer to the Company's filings with the Securities and Exchange Commission, including, but not limited to, the risk factors in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. This release reflects management's views as of the date presented.

    All forward-looking statements are necessarily only estimates of future results, and there can be no assurance that actual results will not differ materially from expectations, and, therefore, you are cautioned not to place undue reliance on such statements. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events.

    For more information contact: 
    Star Equity Holdings, Inc.The Equity Group
    Jeffrey E. EberweinLena Cati
    Executive ChairmanVice President
    203-489-9501212-836-9611
    [email protected][email protected]


    Primary Logo

    Get the next $STRR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STRR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $STRR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Palmer Jennifer

    4 - STAR EQUITY HOLDINGS, INC. (0000707388) (Issuer)

    8/18/25 7:24:27 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Fruhbeis Todd Michael

    4 - STAR EQUITY HOLDINGS, INC. (0000707388) (Issuer)

    8/18/25 7:23:28 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Parks Louis A.

    4 - STAR EQUITY HOLDINGS, INC. (0000707388) (Issuer)

    8/18/25 7:22:47 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STRR
    SEC Filings

    View All

    Star Equity Holdings Inc. filed SEC Form 8-K: Other Events

    8-K - STAR EQUITY HOLDINGS, INC. (0000707388) (Filer)

    8/15/25 4:10:33 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Star Equity Holdings Inc.

    10-Q - STAR EQUITY HOLDINGS, INC. (0000707388) (Filer)

    8/13/25 4:12:57 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Star Equity Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - STAR EQUITY HOLDINGS, INC. (0000707388) (Filer)

    8/13/25 8:44:18 AM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STRR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Star Equity Holdings, Inc. Announces 2025 Second Quarter Financial Results

    Q2 2025 revenues increased ~76% to $23.7 million and gross profit increased ~182% to $6.3 million Generated Adjusted EBITDA of $7.0 million Quarter-end Building Solutions backlog stands at $25.7 million OLD GREENWICH, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP)) ("Star" or the "Company"), a diversified holding company, reported today its financial results for the second quarter (Q2) ended June 30, 2025. All 2025 and 2024 amounts in this release are unaudited. Q2 2025 Financial Highlights vs. Q2 2024 (unaudited) Revenues increased by 75.8% to $23.7 million from $13.5 million.Gross profit increased by 182.2% to $6.3 million from $2.2 million.

    8/13/25 8:30:29 AM ET
    $HSON
    $STRR
    Professional Services
    Consumer Discretionary
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Star Equity Holdings, Inc. Declares a Partial Cash Dividend of $0.225 Per Share of 10% Series A Cumulative Perpetual Preferred Stock

    OLD GREENWICH, Conn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP)) ("Star" or the "Company"), a diversified holding company, announced today that its Board of Directors declared a partial cash dividend to holders of the Company's 10% Series A Cumulative Perpetual Preferred Stock ("Star Preferred Stock") of $0.225 per share. The record date for this dividend is August 21, 2025 and the payment date is September 10, 2025. As previously disclosed, on May 21, 2025, Hudson Global, Inc., a Delaware corporation ("Hudson"), HSON Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Hudson ("Merger Sub"), and the Company, entered into

    8/8/25 5:15:31 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hudson Global Reports 2025 Second Quarter Results

    OLD GREENWICH, Conn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Hudson Global, Inc. (NASDAQ:HSON) ("Hudson Global" or "the Company"), a leading global total talent solutions company, announced today financial results for the second quarter ended June 30, 2025. 2025 Second Quarter Summary Revenue of $35.5 million decreased 0.5% from the second quarter of 2024 and 0.2% in constant currency.Adjusted net revenue of $18.6 million increased 5.8% from the second quarter of 2024 and 5.1% in constant currency.Net loss was $0.7 million, or $0.23 per diluted share, compared to net loss of $0.4 million, or $0.15 per diluted share, for the second quarter of 2024. Adjusted net income per d

    8/8/25 8:30:45 AM ET
    $HSON
    $STRR
    Professional Services
    Consumer Discretionary
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STRR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Coleman Richard Kenneth Jr. bought $10,675 worth of shares (2,500 units at $4.27) and bought $4,925 worth of 10% Series A Cumulative Perpetual Preferred Stock (500 units at $9.85), decreasing direct ownership by 93% to 2,500 units (SEC Form 4)

    4 - STAR EQUITY HOLDINGS, INC. (0000707388) (Issuer)

    8/20/24 4:10:35 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Butcher Thatcher bought $3,120 worth of shares (3,000 units at $1.04), increasing direct ownership by 100% to 6,000 units (SEC Form 4)

    4 - STAR EQUITY HOLDINGS, INC. (0000707388) (Issuer)

    12/15/23 1:41:36 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Coleman Richard Kenneth Jr. bought $2,220 worth of shares (2,000 units at $1.11) and bought $18,900 worth of 10% Series A Cumulative Perpetual Preferred Stock (2,000 units at $9.45), decreasing direct ownership by 98% to 2,000 units (SEC Form 4)

    4 - STAR EQUITY HOLDINGS, INC. (0000707388) (Issuer)

    12/4/23 8:25:38 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STRR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Star Equity Holdings Inc.

    SC 13D/A - STAR EQUITY HOLDINGS, INC. (0000707388) (Subject)

    9/10/24 4:04:39 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D/A filed by Star Equity Holdings Inc. (Amendment)

    SC 13D/A - STAR EQUITY HOLDINGS, INC. (0000707388) (Subject)

    9/18/23 4:05:02 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D/A filed by Star Equity Holdings Inc. (Amendment)

    SC 13D/A - STAR EQUITY HOLDINGS, INC. (0000707388) (Subject)

    8/31/23 5:18:25 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STRR
    Leadership Updates

    Live Leadership Updates

    View All

    Star Equity Holdings, Inc. Appoints Rick Coleman as CEO

    OLD GREENWICH, Conn., April 01, 2022 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP))) ("Star Equity" or the "Company"), a diversified holding company, announced today the appointment of Richard ("Rick") K. Coleman, Jr. as Chief Executive Officer, effective April 1, 2022. In addition, Mr. Coleman will be nominated to serve as a director at the Company's upcoming annual meeting of shareholders. Mr. Coleman is a seasoned executive who brings to Star Equity extensive CEO leadership and board-level experience with numerous public and private companies. He was appointed as Star Equity's Chief Operating Officer in January 2022 and has provided valuable insights and direction

    4/1/22 8:00:00 AM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Star Equity Holdings, Inc. Adds Richard Coleman as Chief Operating Officer

    OLD GREENWICH, Conn., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP))) ("Star Equity" or the "Company"), a diversified holding company, announced today the appointment of Richard K. Coleman, Jr. ("Rick") as Chief Operating Officer, effective January 1, 2022. Coleman's addition increases the capacity of Star Equity's senior leadership team. In this role, he will oversee the Company's operations, assist its business leaders in achieving their growth and profitability goals, launch new business initiatives, as well as help analyze and integrate future acquisitions. Coleman brings more than 30 years of executive leadership experience with extensive expertis

    12/20/21 8:00:00 AM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Star Equity Holdings, Inc. Appoints John Gildea to its Board of Directors

    OLD GREENWICH, Conn., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP))) ("Star Equity" or the "Company"), a diversified, multi-industry holding company with three business divisions, Healthcare, Construction, and Investments, announced today the appointment of John W. Gildea to its Board of Directors, effective immediately. Mr. Gildea's appointment as independent director expands Star Equity's Board to six members. Mr. Gildea will also serve on the Audit Committee. Mr. Gildea brings over three decades of experience investing in special situation debt and equity of small to middle market companies. He is the founding partner of Gildea Management Co., a fir

    8/6/21 4:38:13 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STRR
    Financials

    Live finance-specific insights

    View All

    Star Equity Holdings, Inc. Announces 2025 Second Quarter Financial Results

    Q2 2025 revenues increased ~76% to $23.7 million and gross profit increased ~182% to $6.3 million Generated Adjusted EBITDA of $7.0 million Quarter-end Building Solutions backlog stands at $25.7 million OLD GREENWICH, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP)) ("Star" or the "Company"), a diversified holding company, reported today its financial results for the second quarter (Q2) ended June 30, 2025. All 2025 and 2024 amounts in this release are unaudited. Q2 2025 Financial Highlights vs. Q2 2024 (unaudited) Revenues increased by 75.8% to $23.7 million from $13.5 million.Gross profit increased by 182.2% to $6.3 million from $2.2 million.

    8/13/25 8:30:29 AM ET
    $HSON
    $STRR
    Professional Services
    Consumer Discretionary
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hudson Global Reports 2025 Second Quarter Results

    OLD GREENWICH, Conn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Hudson Global, Inc. (NASDAQ:HSON) ("Hudson Global" or "the Company"), a leading global total talent solutions company, announced today financial results for the second quarter ended June 30, 2025. 2025 Second Quarter Summary Revenue of $35.5 million decreased 0.5% from the second quarter of 2024 and 0.2% in constant currency.Adjusted net revenue of $18.6 million increased 5.8% from the second quarter of 2024 and 5.1% in constant currency.Net loss was $0.7 million, or $0.23 per diluted share, compared to net loss of $0.4 million, or $0.15 per diluted share, for the second quarter of 2024. Adjusted net income per d

    8/8/25 8:30:45 AM ET
    $HSON
    $STRR
    Professional Services
    Consumer Discretionary
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Star Equity Holdings to Release Second Quarter 2025 Financial Results on August 13

    OLD GREENWICH, Conn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP)), ("Star Equity" or the "Company"), a diversified holding company, announced today that it will release its financial results for the second quarter ended June 30, 2025, before the market opens on Wednesday, August 13, 2025. A conference call is scheduled for 10:00 a.m. ET (7:00 a.m. PT) on August 13, 2025, to discuss the results and management's outlook. The call may be accessed by dialing: Toll Free: 1-833-630-1956International: 1-412-317-1837 A simultaneous webcast of the call may be accessed online from the Events & Presentations link, on the Investor Relations page of the Star Eq

    8/4/25 8:30:30 AM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care